The approvals based on early phase studies regarded especially targeted therapy (anti ROS1, anti ALK, and anti-RET) in NSCLC and some rare disease (medullary and non-medullary thyroid cancer, soft tissue sarcoma, GIST). This evidence concerns the gene ALK and non-small cell lung carcinoma.